Organon Ends Livial Program In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Oraganon will drop all efforts to market its hormone therapy Livial (tibolone) in the United States following a June 1 "not approvable" letter. The company was seeking an indication for treatment of menopausal symptoms
You may also be interested in...
Pfizer Ends Asenapine Collaboration With Organon
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
Pfizer Ends Asenapine Collaboration With Organon
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.
Akzo Nobel Shareholders To Vote On Organon BioSciences IPO
Dutch company’s planned separation of pharmaceuticals business from chemicals/coatings division is expected to be complete in two to three years.